嵌合抗原受体
医学
多发性骨髓瘤
抗原
耐火材料(行星科学)
癌症研究
受体
T细胞
免疫学
内科学
免疫系统
生物
天体生物学
作者
Nikhil C. Munshi,Larry D. Anderson,Nina Shah,Deepu Madduri,Jesús G. Berdeja,Sagar Lonial,Noopur Raje,Yi Lin,David S. Siegel,Albert Oriol,Philippe Moreau,Ibrahim Yakoub‐Agha,Michel Delforge,Michèle Cavo,Hermann Einsele,Hartmut Goldschmidt,Katja Weisel,Alessandro Rambaldi,Donna Reece,Fabio Petrocca
标识
DOI:10.1056/nejmoa2024850
摘要
Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma.
科研通智能强力驱动
Strongly Powered by AbleSci AI